Advancing Gene-Targeted Therapies for Central Nervous System Disorders

A Workshop

April 23rd - 24th
Washington, DC
Session IV: Clinical Trial Design and Regulatory Pathways

- **Translation and treatment paradigm** – explore issues with preclinical models, delivery, considerations for FIH, immune response, dose response, and dose and dose regimen selection. What unique challenges do neuropsychiatric diseases present?

- **Patient access** – discuss recruitment challenges, natural history studies, and opportunities with registries/patient advocacy.

- **Regulatory pathway** – address ethical considerations, issues with standards and harmonization, and overall level of proof required.

- **Risk/benefit and value to patients** – consider how to define meaningful, clinically relevant endpoints, and how to demonstrate efficacy, safety and overall effectiveness over the long run.
  - Specific questions may include, should long term toxicity studies be required (6 months or more)? Should biodistribution and rationale be considered for each gene product or can biosimilars be cross-referenced? What is a biosimilar?